慢性肾脏病患者髋或膝关节置换术后预防性抗凝的血栓或出血风险
在加拿大安大略省≥66岁慢性肾脏病并行髋或膝关节置换术的患者中,比较直接口服抗凝药与低分子肝素预防性抗凝的90天血栓和出血风险。共27 645例患者,DOAC组血栓风险1.5% vs LMWH组2.1%(加权HR 0.75,95%CI 0.59-0.94),出血风险1.3% vs 1.0%(加权HR 1.44,95%CI 1.04-1.99)。
要点
- 老年慢性肾脏病患者关节置换术后,DOAC较LMWH静脉血栓风险更低(加权HR 0.75,95%CI 0.59-0.94)。
- DOAC较LMWH出血风险更高(加权HR 1.44,95%CI 1.04-1.99)。
- 敏感性分析(更严格VTE定义、不同eGFR阈值、仅利伐沙班和依诺肝素)结果一致。
核心结论
- 在老年慢性肾脏病患者中,髋或膝关节置换术后DOAC较LMWH与更低的静脉血栓风险和更高的出血风险相关。
研究设计与样本
- 基于人群的回顾性队列研究,纳入2010至2020年加拿大安大略省≥66岁慢性肾脏病并行髋或膝关节置换术且填写过门诊预防性抗凝处方的成人。
- 共27 645例患者,DOAC组22 943例,LMWH组4 702例。
- DOAC以利伐沙班为主(94.5%),LMWH主要包括依诺肝素(67%)和达肝素(31.5%)。
- 采用重叠加权病因特异性Cox比例风险模型比较DOAC与LMWH的90天静脉血栓和出血风险。
主要发现
- DOAC组静脉血栓发生率为1.5%,LMWH组为2.1%,加权HR 0.75(95%CI 0.59-0.94)。
- DOAC组出血发生率为1.3%,LMWH组为1.0%,加权HR 1.44(95%CI 1.04-1.99)。
- DOAC使用者较LMWH使用者eGFR更高、合并症更少且手术年份更近。
关键数值与推荐
- 静脉血栓和出血通过经验证的算法基于相关诊断和账单代码识别。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic kidney disease (CKD) confers a high risk of thrombosis and bleeding. However, little evidence exists regarding the optimal choice of postoperative thromboprophylaxis in these patients. We conducted a population-based, retrospective cohort study among adults ≥66 years old with CKD undergoing hip or knee arthroplasty who had filled an outpatient prophylactic anticoagulant prescription between 2010 and 2020 in Ontario, Canada. The primary outcomes of venous thrombosis (VTE) and hemorrhage were identified by validated algorithms using relevant diagnoses and billing codes. Overlap-weighted cause-specific Cox proportional hazard models were used to examine the association of direct oral anticoagulants (DOAC) on the 90-day risk of VTE and hemorrhage compared with low-molecular-weight heparin (LMWH). A total of 27 645 patients were prescribed DOAC (N = 22 943) or LMWH (N = 4702) after arthroplasty. Rivaroxaban was the predominant DOAC (94.5%), while LMWH mainly included enoxaparin (67%) and dalteparin (31.5%). DOAC users had higher eGFRs, fewer co-morbidities, and surgery in more recent years compared to LMWH users. After weighing, DOAC (compared with LMWH) was associated with a lower risk of VTE (DOAC: 1.5% vs. LMWH: 2.1%, weighted hazard ratio [HR] 0.75, 95% confidence interval [CI] 0.59-0.94) and a higher risk of hemorrhage (DOAC: 1.3% vs. LMWH: 1.0%, weighted HR 1.44, 95% CI 1.04-1.99). Additional analyses including a more stringent VTE defining algorithm, different eGFR cut-offs, and limiting to rivaroxaban and enoxaparin showed consistent findings. Among elderly adults with CKD, DOAC was associated with a lower VTE risk and a higher hemorrhage risk compared to LMWH following hip or knee arthroplasty.
引用
- Wang TF, Grubic N, Carrier M, et al. Risk of venous thromboembolism or hemorrhage among individuals with chronic kidney disease on prophylactic anticoagulant after hip or knee arthroplasty. Am J Hematol. 2023. PMID: 37340812. doi:10.1002/ajh.26994
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。